{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:30:08Z","timestamp":1790094608320,"version":"4.0.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00702-024-02777-z","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T12:01:51Z","timestamp":1715688111000},"page":"1209-1216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Sublingual apomorphine in the treatment of Parkinson\u2019s disease"],"prefix":"10.1007","volume":"131","author":[{"given":"Jan","family":"Kassubek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8574-3297","authenticated-orcid":false,"given":"Wolfgang H.","family":"Jost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,14]]},"reference":[{"issue":"12","key":"2777_CR1","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41582-018-0083-y","volume":"14","author":"A Antonini","year":"2018","unstructured":"Antonini A, Jenner P (2018) Apomorphine infusion in advanced Parkinson disease. Nat Rev Neurol 14(12):693\u2013694. https:\/\/doi.org\/10.1038\/s41582-018-0083-y","journal-title":"Nat Rev Neurol"},{"key":"2777_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.parkreldis.2019.02.002","volume":"62","author":"C Buhmann","year":"2019","unstructured":"Buhmann C, Bihler M, Emich K, Hidding U, P\u00f6tter-Nerger M, Gerloff C, Niessen A, Fl\u00fcgel T, Koseki JC, Nienstedt JC, Pflug C (2019) Pill swallowing in Parkinson\u2019s disease: a prospective study based on flexible endoscopic evaluation of swallowing. Parkinsonism Relat Disord 62:51\u201356. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.02.002","journal-title":"Parkinsonism Relat Disord"},{"key":"2777_CR3","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s40263-019-00661-z","volume":"33","author":"F Carbone","year":"2019","unstructured":"Carbone F, Djamshidian A, Seppi K, Poewe W (2019) Apomorphine for Parkinson\u2019s Disease: efficacy and safety of current and new formulations. CNS Drugs 33:905\u2013918. https:\/\/doi.org\/10.1007\/s40263-019-00661-z","journal-title":"CNS Drugs"},{"issue":"11","key":"2777_CR4","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.clinthera.2005.11.016","volume":"27","author":"JJ Chen","year":"2005","unstructured":"Chen JJ, Obering C (2005) A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson\u2019s disease. Clin Ther 27(11):1710\u20131724. https:\/\/doi.org\/10.1016\/j.clinthera.2005.11.016","journal-title":"Clin Ther"},{"key":"2777_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.parkreldis.2018.02.001","volume":"51","author":"KL Chou","year":"2018","unstructured":"Chou KL, Stacy M, Simuni T, Miyasaki J, Oertel WH, Sethi K, Fernandez HH, Stocchi F (2018) The spectrum of off in Parkinson\u2019s disease: what have we learned over 40 years? Parkinsonism Relat Disord 51:9\u201316. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.02.001","journal-title":"Parkinsonism Relat Disord"},{"key":"2777_CR6","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1002\/mds.29066","volume":"37","author":"G Deuschl","year":"2022","unstructured":"Deuschl G, Antonini A, Costa J, \u015ami\u0142owska K, Berg D, Corvol JC, Fabbrini G, Ferreira J, Foltynie T, Mir P, Schrag A, Seppi K, Taba P, Ruzicka E, Selikhova M, Henschke N, Villanueva G, Moro E (2022) European Academy of Neurology\/Movement Disorder Society-European Section Guideline on the treatment of Parkinson\u2019s Disease: I. Invasive therapies. Mov Disord 37:1360\u20131374. https:\/\/doi.org\/10.1002\/mds.29066","journal-title":"Mov Disord"},{"key":"2777_CR7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40120-022-00435-8","volume":"12","author":"M Fabbri","year":"2023","unstructured":"Fabbri M, Barbosa R, Rascol O (2023) Off-time Treatment options for Parkinson\u2019s Disease. Neurol Ther 12:391\u2013424. https:\/\/doi.org\/10.1007\/s40120-022-00435-8","journal-title":"Neurol Ther"},{"key":"2777_CR8","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1002\/mds.29193","volume":"37","author":"JJ Ferreira","year":"2022","unstructured":"Ferreira JJ, Poewe W, Rascol O, Stocchi F, Antonini A, Moreira J, Guimar\u00e3es B, Rocha JF, Soares-da-Silva P (2022) Effect of Opicapone on Levodopa Pharmacokinetics in patients with fluctuating Parkinson\u2019s Disease. Mov Disord 37:2272\u20132283. https:\/\/doi.org\/10.1002\/mds.29193","journal-title":"Mov Disord"},{"key":"2777_CR9","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/mds.22112","volume":"24","author":"D Grosset","year":"2009","unstructured":"Grosset D, Antonini A, Canesi M, Pezzoli G, Lees A, Shaw K, Cubo E, Martinez-Martin P, Rascol O, Negre-Pages L, Senard A, Schwarz J, Strecker K, Reichmann H, Storch A, L\u00f6hle M, Stocchi F, Grosset K (2009) Adherence to antiparkinson medication in a multicenter European study. Mov Disord 24:826\u2013832. https:\/\/doi.org\/10.1002\/mds.22112","journal-title":"Mov Disord"},{"key":"2777_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.parkreldis.2019.12.012","volume":"71","author":"DG Grosset","year":"2020","unstructured":"Grosset DG, Dhall R, Gurevich T, Kassubek J, Poewe WH, Rascol O, Rudzinska M, Cormier J, Sedkov A, Oh C (2020) Inhaled levodopa in Parkinson\u2019s disease patients with OFF periods: a randomized 12-month pulmonary safety study. Parkinsonism Relat Disord 71:4\u201310. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.12.012","journal-title":"Parkinsonism Relat Disord"},{"key":"2777_CR11","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/mds.22759","volume":"24","author":"RA Hauser","year":"2009","unstructured":"Hauser RA, Auinger P, Oakes D, Parkinson Study Group (2009) Levodopa response in early Parkinson\u2019s disease. Mov Disord 24:2328\u20132336. https:\/\/doi.org\/10.1002\/mds.22759","journal-title":"Mov Disord"},{"key":"2777_CR12","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/mds.26697","volume":"31","author":"RA Hauser","year":"2016","unstructured":"Hauser RA, Olanow CW, Dzyngel B, Bilbault T, Shill H, Isaacson S, Dubow J, Agro A (2016) Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson\u2019s disease. Mov Disord 31:1366\u20131372. https:\/\/doi.org\/10.1002\/mds.26697","journal-title":"Mov Disord"},{"key":"2777_CR13","doi-asserted-by":"publisher","unstructured":"Hauser RA, Espay AJ, Ellenbogen AL, Fernandez HH, Isaacson SH, LeWitt PA, Ondo WG, Pahwa R, Schwarz J, Stocchi F, Zeitlin L, Banisadr G, Fisher S, Visser H, D\u2019Souza R (2023A) IPX203 vs Immediate-Release Carbidopa-Levodopa for the treatment of Motor fluctuations in Parkinson Disease: the RISE-PD Randomized Clinical Trial. JAMA Neurol 80:1062\u20131069. https:\/\/doi.org\/10.1001\/jamaneurol.2023.2679","DOI":"10.1001\/jamaneurol.2023.2679"},{"key":"2777_CR14","doi-asserted-by":"publisher","unstructured":"Hauser RA, Ondo WG, Zhang Y, Bowling A, Navia B, Pappert E, Isaacson SH, CTH-301 Study Investigators (2023B) Dose Optimization of Apomorphine Sublingual Film for OFF Episodes in Parkinson\u2019s Disease: Is the Prophylactic Use of an Antiemetic Necessary? J Parkinsons Dis 13:403\u2013414. https:\/\/doi.org\/10.3233\/JPD-223537","DOI":"10.3233\/JPD-223537"},{"key":"2777_CR15","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s00702-022-02520-6","volume":"129","author":"M H\u00f6llerhage","year":"2022","unstructured":"H\u00f6llerhage M, Klietz M, H\u00f6glinger GU (2022) Disease modification in parkinsonism: obstacles and ways forward. J Neural Transm (Vienna) 129:1133\u20131153. https:\/\/doi.org\/10.1007\/s00702-022-02520-6","journal-title":"J Neural Transm (Vienna)"},{"key":"2777_CR16","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.parkreldis.2020.08.028","volume":"79","author":"JS Hui","year":"2020","unstructured":"Hui JS, Fox SH, Neeson W, Bhargava P, Pappert E, Blum D, Navia B, CTH-300 Study Investigators (2020) Open-label titration of apomorphine sublingual film in patients with Parkinson\u2019s disease and OFF episodes. Parkinsonism Relat Disord 79:110\u2013116. https:\/\/doi.org\/10.1016\/j.parkreldis.2020.08.028","journal-title":"Parkinsonism Relat Disord"},{"key":"2777_CR17","doi-asserted-by":"publisher","unstructured":"Isaacson SH, Achari M, Bhidayasiri R, Comella C, Farmer JG, Gupta F, Jones S, Kreitzman D, Kremens D, Lewis SJG, Poewe W, Tolosa E, Campos C, Gibbs SN, Broder MS (2023A) Expert Consensus on the Use of On-Demand Treatments for OFF Episodes in Parkinson\u2019s Disease: A Modified Delphi Panel. Mov Disord Clin Pract 10:652\u2013657. https:\/\/doi.org\/10.1002\/mdc3.13690","DOI":"10.1002\/mdc3.13690"},{"key":"2777_CR18","doi-asserted-by":"publisher","unstructured":"Isaacson SH, Bowling A, Zhang I, Pappert E, Stocchi F, CTH-300 and CTH-301 Study Investigators (2023B) Motor response with apomorphine sublingual film and levodopa in patients with OFF episodes. Neurodegener Dis Manag 13:75\u201384. https:\/\/doi.org\/10.2217\/nmt-2022-0038","DOI":"10.2217\/nmt-2022-0038"},{"key":"2777_CR19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1055\/a-1158-9281","volume":"89","author":"WH Jost","year":"2021","unstructured":"Jost WH, Ebersbach G, Kassubek J, Klebe S, T\u00f6nges L (2021) New Therapeutic options for the individualised titration of levodopa. Fortschr Neurol Psychiatr 89:23\u201328. https:\/\/doi.org\/10.1055\/a-1158-9281","journal-title":"Fortschr Neurol Psychiatr"},{"key":"2777_CR20","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s00115-021-01237-3","volume":"93","author":"WH Jost","year":"2022","unstructured":"Jost WH, Buhmann C, Classen J, Eggert K, Kohl Z, Outeiro T, T\u00f6nges L, Woitalla D, Reichmann H (2022) Relevance of COMT inhibitors in the treatment of motor fluctuations. Nervenarzt 93:1035\u20131045. https:\/\/doi.org\/10.1007\/s00115-021-01237-3","journal-title":"Nervenarzt"},{"key":"2777_CR21","doi-asserted-by":"publisher","unstructured":"Jost WH, Kulisevsky J, LeWitt PA Inhaled levodopa for threatening impending OFF episodes in managing Parkinson\u2019s disease. J Neural Transm (Vienna) 130:821\u2013826. https:\/\/doi.org\/10.1007\/s00702-023-02636-3","DOI":"10.1007\/s00702-023-02636-3"},{"key":"2777_CR22","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE (2015) Parkinson\u2019s disease. Lancet 386:896\u2013912. https:\/\/doi.org\/10.1016\/S0140-6736(14)61393-3","journal-title":"Lancet"},{"key":"2777_CR23","doi-asserted-by":"publisher","first-page":"175628642312092","DOI":"10.1177\/17562864231209240","volume":"16","author":"J Kassubek","year":"2023","unstructured":"Kassubek J, Stocchi F, Balaguer Martinez E, Pahwa R, Ondo W, Zhang Y, Bowling A, Pappert E, Isaacson S, Wu S, for the CTH-302 Study Investigators (2023) Feasibility of home dose optimization of apomorphine sublingual film in Parkinson\u2019s disease patients with OFF episodes: results from the dose optimization phase of an open-label, randomized crossover study. Ther Adv Neurol Disord 16:17562864231209240. https:\/\/doi.org\/10.1177\/17562864231209240","journal-title":"Ther Adv Neurol Disord"},{"key":"2777_CR24","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41531-022-00421-9","volume":"8","author":"B Labeit","year":"2022","unstructured":"Labeit B, Berkovich E, Claus I, Roderigo M, Schwake AL, Izgelov D, Mimrod D, Ahring S, Oelenberg S, Muhle P, Zentsch V, Wenninger F, Suntrup-Krueger S, Dziewas R, Warnecke T (2022) Dysphagia for medication in Parkinson\u2019s disease. NPJ Parkinsons Dis 8:156. https:\/\/doi.org\/10.1038\/s41531-022-00421-9","journal-title":"NPJ Parkinsons Dis"},{"key":"2777_CR25","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1111\/ene.15734","volume":"30","author":"V Leta","year":"2023","unstructured":"Leta V, Klingelhoefer L, Longardner K, Campagnolo M, Levent H\u00c7, Aureli F, Metta V, Bhidayasiri R, Chung-Faye G, Falup-Pecurariu C, Stocchi F, Jenner P, Warnecke T, Ray Chaudhuri K (2023) Gastrointestinal barriers to levodopa transport and absorption in Parkinson\u2019s disease. Eur J Neurol 30:1465\u20131480. https:\/\/doi.org\/10.1111\/ene.15734. International Parkinson and Movement Disorders Society Non-Motor Parkinson\u2019s Disease Study Group","journal-title":"Eur J Neurol"},{"key":"2777_CR26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1474-4422(18)30405-8","volume":"18","author":"PA LeWitt","year":"2019","unstructured":"LeWitt PA, Hauser RA, Pahwa R, Isaacson SH, Fernandez HH, Lew M, Saint-Hilaire M, Pourcher E, Lopez-Manzanares L, Waters C, Rudz\u00ednska M, Sedkov A, Batycky R, Oh C, SPAN-PD Study Investigators (2019) Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol 18:145\u2013154. https:\/\/doi.org\/10.1016\/S1474-4422(18)30405-8","journal-title":"Lancet Neurol"},{"key":"2777_CR27","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/mds.27690","volume":"34","author":"CW Olanow","year":"2019","unstructured":"Olanow CW (2019) Levodopa is the best symptomatic therapy for PD: nothing more, nothing less. Mov Disord 34:812\u2013815. https:\/\/doi.org\/10.1002\/mds.27690","journal-title":"Mov Disord"},{"key":"2777_CR28","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S1474-4422(19)30396-5","volume":"19","author":"CW Olanow","year":"2020","unstructured":"Olanow CW, Factor SA, Espay AJ, Hauser RA, Shill HA, Isaacson S, Pahwa R, Leinonen M, Bhargava P, Sciarappa K, Navia B, Blum D, CTH-300 Study investigators (2020) Apomorphine sublingual film for off episodes in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurol 19:135\u2013144. https:\/\/doi.org\/10.1016\/S1474-4422(19)30396-5","journal-title":"Lancet Neurol"},{"key":"2777_CR29","doi-asserted-by":"publisher","unstructured":"Olanow CW, Poewe W, Rascol O, Stocchi F (2021A) On-Demand Therapy for OFF Episodes in Parkinson\u2019s Disease. Mov Disord 36:2244\u20132253. https:\/\/doi.org\/10.1002\/mds.28726","DOI":"10.1002\/mds.28726"},{"key":"2777_CR30","doi-asserted-by":"publisher","unstructured":"Olanow CW, Stocchi F, Peckham EL, De Pandis MF, Sciarappa K, Navia B (2021B) Dose optimization of apomorphine sublingual film for treating OFF episodes in Parkinson\u2019s disease. Parkinsonism Relat Disord 93:27\u201330. https:\/\/doi.org\/10.1016\/j.parkreldis.2021.10.025","DOI":"10.1016\/j.parkreldis.2021.10.025"},{"key":"2777_CR31","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s00702-019-02034-8","volume":"126","author":"D Richter","year":"2019","unstructured":"Richter D, Bartig D, Jost W, J\u00f6rges C, Stumpe B, Gold R, Krogias C, T\u00f6nges L (2019) Dynamics of device-based treatments for Parkinson\u2019s disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation. J Neural Transm (Vienna) 126:879\u2013888. https:\/\/doi.org\/10.1007\/s00702-019-02034-8","journal-title":"J Neural Transm (Vienna)"},{"key":"2777_CR32","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1093\/brain\/123.11.2297","volume":"123","author":"A Schrag","year":"2000","unstructured":"Schrag A, Quinn N (2000) Dyskinesias and motor fluctuations in Parkinson\u2019s disease. A community-based study. Brain 123:2297\u20132305. https:\/\/doi.org\/10.1093\/brain\/123.11.2297","journal-title":"Brain"},{"key":"2777_CR33","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s00702-010-0424-5","volume":"117","author":"M Stacy","year":"2010","unstructured":"Stacy M (2010) The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson\u2019s disease. J Neural Transm (Vienna) 117:837\u2013846. https:\/\/doi.org\/10.1007\/s00702-010-0424-5","journal-title":"J Neural Transm (Vienna)"},{"key":"2777_CR34","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.parkreldis.2013.10.027","volume":"20","author":"F Stocchi","year":"2014","unstructured":"Stocchi F, Antonini A, Barone P, Tinazzi M, Zappia M, Onofrj M, Ruggieri S, Morgante L, Bonuccelli U, Lopiano L, Pramstaller P, Albanese A, Attar M, Posocco V, Colombo D, Abbruzzese G, DEEP study group (2014) Early DEtection of wEaring off in Parkinson disease: the DEEP study. Parkinsonism Relat Disord 20:204\u2013211. https:\/\/doi.org\/10.1016\/j.parkreldis.2013.10.027","journal-title":"Parkinsonism Relat Disord"},{"key":"2777_CR35","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/cpdd.1147","volume":"11","author":"F Stocchi","year":"2022","unstructured":"Stocchi F, Peckham EL, De Pandis MF, Sciarappa K, Kleiman R, Agbo F, Olanow CW, Blum D, Navia B (2022) A Randomized Thorough QT Study of Apomorphine Sublingual Film in patients with Parkinson\u2019s Disease. Clin Pharmacol Drug Dev 11:1068\u20131077. https:\/\/doi.org\/10.1002\/cpdd.1147","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2777_CR36","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.3233\/JPD-230072","volume":"13","author":"F Stocchi","year":"2023","unstructured":"Stocchi F, Rascol O, Poewe W, Chaudhuri KR, Kassubek J, Manzanares LL, Zhang Y, Bowling A, Pappert E, Wu S, for the CTH-302 Study Investigators (2023) Apomorphine Sublingual Film compared with Subcutaneous Apomorphine for OFF episodes in Parkinson\u2019s disease: an Open-label, randomized, crossover study. J Parkinsons Dis 13:1329\u20131342. https:\/\/doi.org\/10.3233\/JPD-230072","journal-title":"J Parkinsons Dis"},{"key":"2777_CR37","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1212\/WNL.0b013e318285c0ed","volume":"80","author":"A Storch","year":"2013","unstructured":"Storch A, Schneider CB, Wolz M, St\u00fcrwald Y, Nebe A, Odin P, Mahler A, Fuchs G, Jost WH, Chaudhuri KR, Koch R, Reichmann H, Ebersbach G (2013) Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 80:800\u2013809. https:\/\/doi.org\/10.1212\/WNL.0b013e318285c0ed","journal-title":"Neurology"},{"key":"2777_CR38","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/mdc3.13425","volume":"9","author":"LJ Williams","year":"2022","unstructured":"Williams LJ, Griffith J, Waller SE, Kwan VP, Fung VSC (2022) The profound impact of gastrointestinal stasis on Levodopa Response in Parkinson\u2019s Disease. Mov Disord Clin Pract 9:394\u2013396. https:\/\/doi.org\/10.1002\/mdc3.13425","journal-title":"Mov Disord Clin Pract"},{"key":"2777_CR39","doi-asserted-by":"publisher","first-page":"e2443","DOI":"10.1212\/WNL.0000000000201204","volume":"99","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, He X, Mo C, Liu X, Li J, Yan Z, Qian Y, Lai Y, Xu S, Yang X, Xiao Q (2022) Association between Microbial Tyrosine Decarboxylase Gene and Levodopa responsiveness in patients with Parkinson Disease. Neurology 99:e2443\u2013e2453. https:\/\/doi.org\/10.1212\/WNL.0000000000201204","journal-title":"Neurology"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-024-02777-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-024-02777-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-024-02777-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T15:10:18Z","timestamp":1729264218000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-024-02777-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,14]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2777"],"URL":"https:\/\/doi.org\/10.1007\/s00702-024-02777-z","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,14]]},"assertion":[{"value":"1 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JK is a consultant and speaker for AbbVie, Bial, Biogen, Desitin, Esteve, Novartis, STADA, UCB Pharma, and Zambon; in addition, he is Specialty Chief Editor for Frontiers in Neurology (section Applied Neuroimaging) and Associate Editor (Neurology) for Therapeutic Advances in Chronic Disease. WHJ is a consultant and speaker for Abbvie, Bial, Desitin, Esteve, STADA, Zambon. JS is a consultant and speaker for Abbvie, Bial, GE, UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}